Skip to main content
Premium Trial:

Request an Annual Quote

Alejandro Zaffaroni, Harry Stylli, Steven Zaniboni, Toni Schu

Premium

Affymetrix co-founder Alejandro Zaffaroni last week received the Gregory Pincus Award from the Worcester Foundation for Biological Research in honor of the "many accomplishments of his half century of work in drug discovery and biological research."

The Uruguayan-born founder of Alza is also credited with founding DNAX, Affymax, Symyx Technologies, Maxygen, SurroMed, and, most recently, Alexza MDC. Zaffaroni was also involved in the creation of Perlegen, an Affymetrix spin-off that launched in 1994.

Zaffaroni received his BS from the University of Montevideo in Uruguay in 1941 and received a PhD in biochemistry from the University of Rochester in 1949.

The Pincus award, established in 1969, is given annually by the Worcester Foundation at the University of Massachusetts Medical Center to recognize individuals who are pioneers in the fields of endocrine and reproductive biology and honors Gregory Goodwin Pincus, a reproductive physiologist known for developing the world's first oral contraceptive pill.


Sequenom has named Harry Stylli as its new president and CEO, the company said last week. He also has been elected to the company's board of directors.

Stylli previously served as president and CEO of Xencor, a privately held biotechnology company, and will remain on that company's board of directors. He also serves as a director of Molecular Insight Pharmaceuticals, a private biotechnology company, and is an advisor to Nanosyn, a private medicinal chemistry company.

Stylli co-founded Aurora Biosciences in 1995 where he held various senior-level administrative positions. In 2001, he played a role in Vertex Pharmaceuticals' acquisition of Aurora for about $600 million and Panvera, wholly owned subsidiaries of Vertex Pharmaceuticals.

Prior to Aurora, Stylli served as president and CEO of CovX Pharmaceuticals and held research positions at Glaxo-Wellcome Research. He holds a BS from the University of East London and a PhD from London University's Faculty of Medicine. He received his MBA from the UK's Open University.

Stylli replaces Steven Zaniboni, who had been serving as interim CEO following the resignation of Toni Schuh in February.

 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.